REBYOTA
spdr s&p biotech,ishares biotechnology,ferring
['rp3 ', 'rp3', '$ibb', '$xbi']
four analyses of data highlights the effectiveness of rebyota (fecal microbiota) the first fda-approved microbiome-based therapy for preventing recurrent c. difficile infection, as presented at ddw 2023. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt